Comparative long-term sedation efficacy of remimazolam vs propofol in malignant patients with mechanical ventilation: an exploratory non-inferiority randomized study

Keeping Breathing Support as Comfortable as Possible

For many people with cancer, a stay in the intensive care unit (ICU) on a breathing machine is one of the most daunting parts of treatment. These patients usually need medicines to keep them calm and comfortable while a ventilator does the work of breathing. This study asks a practical bedside question with big human consequences: can a newer calming drug, remimazolam, keep ventilated cancer patients as safely and comfortably sedated as the long‑standing favorite, propofol—and might it have extra benefits for the body’s inflammatory response?

Two Calming Medicines Under the Microscope

Propofol has been the usual choice to keep ICU patients lightly asleep: alert enough to be safely awakened, but relaxed enough not to fight the ventilator. Remimazolam is a newer drug in the same broad family as familiar sleeping pills, but it is designed to work and wear off quickly. Researchers at a cancer hospital in Beijing ran a randomized trial in adults with malignancies who needed more than a day of mechanical ventilation. One group received infusions of remimazolam, the other propofol, and both also got standard pain relief. The goal was to hold each patient in a light, steady state of calm, measured by a bedside scoring tool that tracks how restless or drowsy someone appears.

Staying Calm Without Staying Too Deep

The central test was whether remimazolam could match propofol in keeping patients within that desired “lightly sedated” window over the first two days. On this front, the two drugs were essentially neck‑and‑neck. At 6, 24, and 48 hours after starting treatment, roughly 80–90% of patients in both groups were in the target range, and the overall proportion of time spent at the right level of calm was almost identical. When nurses and doctors checked many times over 48 hours, remimazolam actually hit the desired range in a slightly higher share of individual checks, but the main message is that both approaches provided reliable, controllable comfort.

Breathing Tubes, ICU Days, and Safety

Patients and families care deeply about how long a breathing tube stays in and how long an ICU stay lasts. Here, too, the drugs performed similarly. About three‑quarters of patients in each group were off the ventilator within a week, and the typical ICU stay was just over a week in both groups. Survival at 28 days was very high and nearly identical. The need for an extra sedative, and common complications such as low blood pressure or delirium, occurred at comparable rates in both groups. In other words, switching from propofol to remimazolam did not make patients sicker, nor did it clearly shorten or prolong their time on life support in this pilot trial.

Hints About the Body’s Inflammatory Response

The team also explored whether the sedative choice might subtly change the body’s inflammatory “weather,” especially in patients with sepsis, a severe infection that often lands people in the ICU. They followed a simple blood marker called the neutrophil‑to‑lymphocyte ratio, which rises when inflammation is high. For the overall group, this marker behaved similarly with both drugs. But in a smaller subgroup of patients with sepsis, those given remimazolam showed lower values at 24 and 48 hours than those given propofol, hinting that their inflammation may have eased more quickly. The researchers are careful to stress that this finding is exploratory: the numbers were small, the study was not designed around this question, and it would be premature to claim that remimazolam directly tempers harmful inflammation in people.

What This Means for Critically Ill Cancer Patients

For cancer patients on ventilators, this work suggests that remimazolam is a viable alternative to propofol for long‑term calming in the ICU. It appears just as effective at maintaining a comfortable, lightly sedated state, with similar chances of coming off the breathing machine, similar lengths of ICU stay, and no extra safety concerns in this study. Early signs that it might also nudge the immune system toward a less inflamed state in certain infections are intriguing but far from proven. Larger, more powerful trials will be needed to confirm whether this newer drug offers advantages beyond comfort, but for now it gives ICU teams another flexible option for one of the most delicate balances in critical care: keeping patients safely calm without holding them back from recovery.

Citation: Yuan, Zn., Cao, F., Wang, Hj. et al. Comparative long-term sedation efficacy of remimazolam vs propofol in malignant patients with mechanical ventilation: an exploratory non-inferiority randomized study. Sci Rep 16, 13900 (2026). https://doi.org/10.1038/s41598-026-47017-4

Keywords: ICU sedation, mechanical ventilation, cancer patients, remimazolam, propofol